Amgen (AMGN) closed at $270.90 in the latest trading session, marking a +0.76% move from the prior day. This move outpaced the S&P 500's daily gain of 0.63%. Meanwhile, the Dow gained 0.2%, and the Nasdaq, a tech-heavy index, added 0.82%.Heading into today, shares of the world's largest biotech drugmaker had lost 5.23% over the past month, lagging the Medical sector's gain of 0.91% and the S&P 500's gain of 1.76% in that time.The investment community will be closely monitoring the performance of Amgen in it ...

Key PointsAs market hype surrounds AI and potential Federal Reserve interest rate cuts loom, investors are presented with a junction of prudence and opportunity.Overlooked and oversold large-cap stocks offer compelling dividend yields for investors seeking income and potential capital appreciation.High dividend-yielding stocks prove advantageous in low-interest rate environments, offering stability and income for investors seeking alternatives to bonds and savings accounts.5 stocks we like better than BHP G ...

Mario Tama/Getty Images News Overview Recently, I've been analyzing different dividend ETFs to determine how they consider a company qualified for a spot in their holdings. Typically, the things that these funds filter for are dividend growth consistency, the CAGR (compound annual growth rate) of the dividend, free cash flow & EPS growth, and a historically positive total return. Reviewing the popular Schwab U.S. Dividend Equity ETF (SCHD), I noticed that Amgen (NASDAQ:AMGN) made the top ten holdings list. ...

文章核心观点 - 全球抗肥胖药物(AOM)行业市场规模有望从目前的60亿美元增长至2030年的1000亿美元,增长超过16倍[2] - 抗肥胖药物行业受益于与糖尿病等相关疾病的治疗需求,以及新冠疫情导致的集体增重[3] 行业和公司总结 诺和诺德(Novo Nordisk, NVO) - 诺和诺德是行业内的领军企业,今年以来股价已经上涨超过33%,过去52周涨幅超过92%[4] - 投资者对公司新药Amycretin的临床1期试验数据反应积极,该药物在12周内可以带来超过13%的减重效果,优于公司现有药物Wegovy[6] - 公司2024年和2025年的收入预计将分别达到415.7亿美元和493.3亿美元,业绩表现出色[7] 安进(Amgen, AMGN) - 安进正在进行早期临床试验,研发一款实验性的抗肥胖药物,初步数据显示该药物可以带来显著的减重效果且安全性可接受[9] - 尽管AMGN股价今年以来下跌超过8%,但分析师预计公司2024年和2025年收入将分别增长17.1%和3.4%[11] - 目前AMGN股价估值仅为15.19倍滚动市盈率,分析师给予"中性买入"评级,平均目标价为312美元,较当前价格有超过14%的上涨空间[12] 辉瑞(Pfizer, PFE) - 辉瑞曾在新冠疫苗研发中取得成功,但2022年随着疫情影响减弱,PFE股价也大幅下跌[13] - 公司曾在去年12月宣布放弃每日两次服用的口服减重药物danuglipron,但仍在开发每日一次服用的新版本,预计今年上半年将有临床数据公布[14][15] - 分析师对PFE股票给予"中性买入"评级,目标价为31.18美元,较当前价格有超过16%的上涨空间,高端目标价甚至达到45美元,预计可实现68%的涨幅[16]

SPROUT 52-Week Data Demonstrate Durable Response and Consistent Safety Profile of Oral Otezla in Children with Moderate to Severe Plaque Psoriasis Late-Breaking Phase 3 Study of Otezla in Palmoplantar Pustulosis Achieves Primary and Secondary Endpoints at 16 Weeks THOUSAND OAKS, Calif., March 9, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new, 52-week results from the Phase 3 SPROUT study examining the use of Otezla® (apremilast) in children and adolescents aged 6 to 17 years with moderate to s ...

6 Of Goldman Sachs Top 2024 Stock Picks Also Pay Big Dividends Chris Hondros / Getty Images The Artificial Intelligence rally over the last year, led by the so-called “Magnificent 7,” has been fantastic if you owned those stocks. However, most of the S&P 500 is treading water and will not likely ever catch up to the hype-driven AI stocks soon.With the market trading at all-time highs, investors will likely be lured into a false sense of financial security. The reality is the United States could be set for ...

The board of directors of General Dynamics today declared a regular quarterly dividend of $1.42 per share on the company's common stock, payable May 10, 2024, to shareholders of record on April 12, 2024. This is the 27th consecutive annual dividend increase authorized by the General Dynamics board and represents a 7.6% increase over last year's dividend.10 mREITs With Impressive Yields »Amgen today announced that its Board of Directors declared a $2.25 per share dividend for the second quarter of 2024. The ...

THOUSAND OAKS, Calif., March 6, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.25 per share dividend for the second quarter of 2024. The dividend will be paid on June 7, 2024, to all stockholders of record as of the close of business on May 17, 2024. About Amgen Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This a ...

Amgen (AMGN) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.Shares of this world's largest biotech drugmaker have returned -12.5% over the past month versus the Zacks S&P 500 composite's +2.9% change. The Zacks Medical - Biomedical and Genetics industry, to which Amgen belongs, has gained 1% over this period. Now the key question is: Where could the stock be headed in the near term?Wh ...

业绩总结 - Amgen公司在2023年的Repatha和EVENITY产品均实现了强劲的销量增长，分别为37%和44%[1] - TEZSPIRE在2023财年实现了5.67亿美元的销售额，覆盖率扩大至80%[1] - Amgen预计2023年第一季度的产品销售额将较上年同期增长20%，达到61亿美元[3] 新产品和新技术研发 - MariTide是一种针对肥胖症的新型药物，临床试验显示在12周内可实现14.5%的体重减轻[2] - Amgen的新药Olpasiran在心血管结局试验中已快速招募了7000多名患者[2] - Amgen计划在2024年推出多个潜在的首创或最佳类药物，包括MariTide和Olpasiran[3] 市场扩张和并购 - Horizon交易预计在第三年实现至少5亿美元的前税成本协同效应[3] 未来展望 - TEZSPIRE正在研究多种额外适应症，预计在今年上半年公布COPD数据[2] - TEZSPIRE将在下半年发布Phase II COPD数据和Phase III慢性鼻窦炎伴鼻息肉数据[7] 其他新策略和有价值的信息 - Amgen的稀有病业务以TEPEZZA、KRYSTEXXA、UPLIZNA和TAVNEOS为核心，已在沙特阿拉伯获得批准[1] - MariTide认为其药物是治疗肥胖症的重要分子，相应的体重减少效果稳定且可复制[5] - Sjögren综合征的治疗方案包括dazodalibep，这是一种CD40配体拮抗剂，可能对患者产生实质性改善[8]